Trump Wins… But Elon Says Get Ready to Brace

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

Margaret Echerd Biography and Net Worth

SVP of Vaxart

Margaret Echerd is Vaxart’s Senior Vice President and Principal Accounting Officer. She is responsible for the Finance, Accounting, Human Resources, Facilities and IT functions of the organization.
Prior to Vaxart, Ms. Echerd was the Controller of Autonomic Technologies, Inc., a medical device company. Ms. Echerd has previously served as Vice President, Corporate Controller of Quotient Technology, Inc., a digital marketing company. Ms. Echerd held various accounting positions at Extreme Networks, Inc., a networking technology company, including Vice President, Corporate Controller, and Chief Accounting Officer. Ms. Echerd who is a certified public accountant in California, received a B.B.A from Texas A&M University and an M.B.A. from Golden Gate University.

What is Margaret Echerd's net worth?: The estimated net worth of Margaret Echerd is at least $200.40 as of September 10th, 2021. Ms. Echerd owns 334 shares of Vaxart stock worth more than $200 as of November 23rd. This net worth estimate does not reflect any other assets that Ms. Echerd may own. Learn More about Margaret Echerd's net worth.
How do I contact Margaret Echerd?: The corporate mailing address for Ms. Echerd and other Vaxart executives is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. Vaxart can also be reached via phone at (650) 550-3500 and via email at [email protected]. Learn More on Margaret Echerd's contact information.
Has Margaret Echerd been buying or selling shares of Vaxart?: Margaret Echerd has not been actively trading shares of Vaxart over the course of the past ninety days. Most recently, Margaret Echerd sold 3,602 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $8.00, for a transaction totalling $28,816.00. Learn More on Margaret Echerd's trading history.
Who are Vaxart's active insiders?: Vaxart's insider roster includes Margaret Echerd (SVP), Wouter Latour (Director), and Sean Tucker (SVP). Learn More on Vaxart's active insiders.
Are insiders buying or selling shares of Vaxart?: During the last year, Vaxart insiders bought shares 1 times. They purchased a total of 20,000 shares worth more than $13,600.00. The most recent insider tranaction occured on June, 18th when Director W. Mark Watson bought 20,000 shares worth more than $13,600.00. Insiders at Vaxart own 2.6% of the company. Learn More about insider trades at Vaxart.
Information on this page was last updated on 6/18/2024.

Margaret Echerd Insider Trading History at Vaxart

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2021	Sell	3,602	$8.00	$28,816.00
9/10/2021	Sell	1,801	$9.10	$16,389.10	334
7/19/2021	Sell	1,800	$8.00	$14,400.00	333
6/9/2021	Sell	47,555	$8.00	$380,440.00	12,333

Margaret Echerd Buying and Selling Activity at Vaxart

Vaxart Company Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Today's Range

Now: $0.60

$0.59

$0.62

50 Day Range

MA: $0.77

$0.58

$0.94

2 Week Range

Now: $0.60

$0.52

$1.54

Volume

1,640,391 shs

Average Volume

2,480,835 shs

Market Capitalization

$136.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

I hate to say I told you so

From WealthPress | Ad

Last month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…

Follow this link right away.